Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CHAPUIS

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Nature Communications|September 26, 2018
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLAK G Paulson, V Voillet, M S McAfee, et al.
Nature Communications|June 5, 2025
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistenceFrancesco Mazziotta, Lauren E Martin, Daniel N Egan, et al.
Nature Medicine|June 26, 2019
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplantAude G Chapuis, Daniel N Egan, Merav Bar, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Research Square|October 20, 2022
CD8<sup>+</sup> T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccinationEmily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Blood|September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Nature Communications|January 3, 2026
A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligandsShihong Zhang, Tzu-Hao Tang, Sinéad Kinsella, et al.
Blood|April 29, 2024
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantationElizabeth F Krakow, Michelle Brault, Corinne Summers, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Nature Communications|September 26, 2018
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLAK G Paulson, V Voillet, M S McAfee, et al.
Nature Communications|June 5, 2025
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistenceFrancesco Mazziotta, Lauren E Martin, Daniel N Egan, et al.
Nature Medicine|June 26, 2019
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplantAude G Chapuis, Daniel N Egan, Merav Bar, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Research Square|October 20, 2022
CD8<sup>+</sup> T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccinationEmily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Blood|September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Nature Communications|January 3, 2026
A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligandsShihong Zhang, Tzu-Hao Tang, Sinéad Kinsella, et al.
Blood|April 29, 2024
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantationElizabeth F Krakow, Michelle Brault, Corinne Summers, et al.
Pageof 11